“I am delighted that Greg has been elected to our Board of Directors,” said Daniel J. O’Connor, President and Chief Executive Officer of Advaxis. “I have had the pleasure of working with Greg for many years and, throughout his career, he has been a key contributor in helping drive the success of organizations. I know he will add value to the board as we continue to move forward with the important work Advaxis is doing to develop new treatments for cancer patients.”
Mr. Mayes joined Advaxis in October 2013, bringing with him more than 20 years of management experience in the pharmaceutical industry. Since joining Advaxis, he has been instrumental in executing on a successful turnaround strategy for the Company which has improved both its financial position and development pipeline. Mr. Mayes has been key to identifying and negotiating partnerships with the Advaxis Lm Technology™ including clinical collaborations with MedImmune and Merck. In addition, Mr. Mayes has helped cultivate a growing base of institutional shareholders.
Prior to Advaxis, Mr. Mayes held executive leadership positions with ImClone Systems, Eli Lilly and AstraZeneca Pharmaceuticals. While at ImClone, he was selected to lead the integration of ImClone with Eli Lilly and also supported the clinical development and commercialization of ERBITUX® (cetuximab). While with Astra Zeneca, Mr. Mayes provided legal support for the development and commercialization of five approved oncology products. Mr. Mayes received his bachelor of science from Syracuse University and a juris doctorate from Temple University School of Law.
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The LmTechnology™, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’ lead Lm Technology™ immunotherapy, axalimogene filolisbac, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three potential indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The U.S. Food and Drug Administration (FDA) has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development.
For additional information on Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn,Facebook, YouTube and Google+.
This media statement contains forward-looking statements, including, but not limited to: statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies; and the safety and efficacy of Advaxis’ proprietary immunotherapies. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’ SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2015, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
Greg Mayes, Executive Vice President and COO
JPA Health Communications